ACP
ONSIZ

Acuta Capital Partners’s Oncobiologics, Inc. Series B Warrant ONSIZ Stock Holding History

Acuta Capital Partners’s Portfolio ONSIZ Stock Details ONSIZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-96,833
Closed -$5K – 96
2017
Q3 		$5K Hold
96,833
– – ﹤0.01% 64
2017
Q2 		$9K Hold
96,833
– – ﹤0.01% 60
2017
Q1 		$48K Hold
96,833
– – 0.01% 67
2016
Q4 		$76K Hold
96,833
– – 0.03% 46
2016
Q3 		$97K Hold
96,833
– – 0.04% 63
2016
Q2 		$44K Buy
+96,833
New +$50.9K 0.02% 64

Other funds holding ONSIZ

CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
MWNA
Marshall Wace North America New York $23.5B AUM 46.46% 1-Year Est. Return
PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
MIM
Monashee Investment Management Boston, Massachusetts $184M AUM 197.43% 1-Year Est. Return

Acuta Capital Partners's ONSIZ Position: Q4 2017 in Review

Acuta Capital Partners sold out of Oncobiologics, Inc. Series B Warrant (ONSIZ) in Q4 2017, closing a stake of 96,833 shares — an estimated $5K sold.

Acuta Capital Partners first reported a position in ONSIZ in Q2 2016 and held it in 6 quarters. The position peaked at $97K in Q3 2016. 8 funds tracked by Wall St. Rank hold ONSIZ as of Q4 2017.

  • Acuta Capital Partners reported no remaining Oncobiologics, Inc. Series B Warrant position as of Q4 2017 after selling out during the quarter.
  • Acuta Capital Partners sold 96,833 Oncobiologics, Inc. Series B Warrant shares in Q4 2017, an estimated $5K.
  • Acuta Capital Partners first reported a position in Oncobiologics, Inc. Series B Warrant in Q2 2016 and held it in 6 quarters.
  • Acuta Capital Partners's Oncobiologics, Inc. Series B Warrant position peaked at $97K in Q3 2016.
  • 8 funds tracked by Wall St. Rank held Oncobiologics, Inc. Series B Warrant as of Q4 2017.

Based on Acuta Capital Partners's 13F filing for Q4 2017, filed 14 Feb 2018.